VERA
Vera Therapeutics Inc.
$37.69
-$0.70(-1.82%)
44
Overall
50
Value
40
Tech
42
Quality
Market Cap
$1.92B
Volume
1.72M
52W Range
$18.76 - $56.05
Target Price
$79.00
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | -- | $1.9M | $1.9M | $2.0M | ||
| Total Revenue | -- | $1.9M | $1.9M | $2.0M | ||
| GROSS PROFIT | ||||||
| Gross Profit | -- | $1.9M | $1.9M | $2.0M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $34.4M | $90.9M | $102.0M | $167.2M | ||
| Research & Development | $22.5M | $69.0M | $78.2M | $126.2M | ||
| Research Expense | $22.5M | $69.0M | $78.2M | $126.2M | ||
| Selling, General & Administrative | $11.9M | $21.9M | $23.8M | $41.0M | ||
| General & Administrative Expenses | $11.9M | $21.9M | $23.8M | $41.0M | ||
| Other Operating Expenses | $-102.0K | $-265.0K | -- | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-34.4M | $-90.9M | $-102.0M | $-167.2M | ||
| EBITDA | $-32.6M | $-88.1M | $-90.0M | $-142.4M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $20.0K | $992.0K | $3.8M | $7.6M | ||
| Intinc | $15.0K | $1.8M | $8.0M | $20.7M | ||
| Net Non-Operating Interest Income/Expense | $-5.0K | $758.0K | $4.2M | $13.1M | ||
| Gain on Sale of Securities | $-892.0K | $-809.0K | $-47.0K | -- | ||
| Other Income/Expense | $-1.8M | $1.1M | $-2.1M | $-2.1M | ||
| Other Special Charges | $10.2M | $1.9M | $1.8M | $1.9M | ||
| SPECIAL ITEMS | ||||||
| Restructring And Mn A Income | $28.0K | -- | -- | -- | ||
| Special Income Charges | $-28.0K | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-32.6M | $-88.1M | $-92.2M | $-144.5M | ||
| Pre-Tax Income | $-32.6M | $-89.1M | $-96.0M | $-152.1M | ||
| INCOME TAX | ||||||
| Tax Provision | $1.0K | $1.0K | $1.0K | $1.0K | ||
| NET INCOME | ||||||
| Net Income | $-32.6M | $-89.1M | $-96.0M | $-152.1M | ||
| Net Income (Continuing Operations) | $-32.6M | $-89.1M | $-96.0M | $-152.1M | ||
| Net Income (Discontinued Operations) | $-32.6M | $-89.1M | $-96.0M | $-152.1M | ||
| Net Income (Common Stockholders) | $-32.6M | $-89.1M | $-96.0M | $-152.1M | ||
| Normalized Income | $-28.5M | -- | -- | -- | ||
| TOTALS | ||||||
| Total Expenses | $34.4M | $90.9M | $102.0M | $167.2M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $13.4M | $26.6M | $42.7M | $55.3M | ||
| Average Shares Outstanding (Diluted) | $13.4M | $26.6M | $42.7M | $55.3M | ||
| Shares Outstanding | $27.1M | $44.3M | $54.5M | $63.7M | ||
| Basic EPS | $-2.43 | $-3.35 | $-2.25 | $-2.75 | ||
| Basic EPS (Continuing Operations) | $-2.43 | $-3.35 | $-2.25 | $-2.75 | ||
| Diluted EPS | $-2.43 | $-3.35 | $-2.25 | $-2.75 | ||
| Diluted EPS (Continuing Operations) | -- | $-3.35 | $-2.25 | $-2.75 | ||
| OTHER METRICS | ||||||
| Gain On Sale Of Business | $2.7M | -- | -- | -- | ||
| Gain On Sale Of P P E | $2.7M | $2.7M | -- | -- | ||
| Other Gand A | $11.9M | $21.9M | $23.8M | $41.0M | ||
| Restruct | $28.0K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VERA | $37.69 | -1.8% | 1.72M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |